Docking and Dynamic Simulation Analysis of P-glycoprotein pumps - Responsible for Chemotherapeutic Resistance post-treatment with Urea and β–mercaptoethanol

Abstract

The designing of cancer chemotherapy has become increasingly sophisticated over years, against disseminated cancer. With increasing advances in research, resistance to these therapies has also been reported over years. Resistance to treatment with anticancer drugs results from a variety of factors including polymorphic variations in patients and genetic differences in tumours. The most common reason for resistance to a broad range of anticancer drugs is influenced by the expression of one or more energy-dependent transporters (p-glycoprotein pumps) that detect and eject anticancer drugs from cells. Deactivating these pumps can help to overcome such resistance. Thus in this current study lead compounds urea and β–mercaptoethanol has been used to alter the structural confirmation of these P-gp (pump proteins) by using molecular docking and dynamic simulation analysis. Urea & β–mercaptoethanol can bind to the target protein with best docking scores of -15.5995 & -10.0501 respectively. Binding of β – mercaptoethanol caused a considerable perturbation in the backbone of the target protein with RMSD value eventually deviating to approximately 1.3 and urea further deviate the value to approximately 1.6. Furthermore decrease in the intra-molecular hydrogen bonds over the simulation period confirms the secondary structural change thus ceasing the biological activity of the target protein.

Keywords

• P-glycoprotein pumps,Urea,β–mercaptoethanol,Molecular Docking,Dynamic Simulation Analysis

References

1. Chang, G.; Roth, C. Structure of MsbA from E. coli: A homolog of the multidrug resistance ATP binding cassette (ABC) transporters. Science 2001, 293, 1793–1800.
2. Sauna, Z.; Ambudkar, S. Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein. The two ATP hydrolysis events in a single catalytic cycle are kinetically similar but affect different functional outcomes. J. Biol. Chem. 2001, 276, 11653–11661.
3. Borst, P.; Elferink, O. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 2002, 71, 537–592.
4. Schinkel, A.; Smit, J.; van Tellingen, O.; Beijnen, J.; Wagenaar, E.; van Deemter, L.; Mol, C.; van der Valk, M.; Robanus-Maandag, R.; te Riele, H.; et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994, 77, 491–502.
5. Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2, 48–58.
6. Szakas, G.; Annereau, J.; Lababidi, S.; Shankavaram, U.; Arciello, A.; Bussey, K.; Reinhold, W.;Guo, Y.; Kruh, G.; Reimers, M.; et al. Predicting drug sensitivity and resistance: Profiling ABC transporter genes in cancer cells. Cancer Cell 2004, 6, 129–137.
7. Hilgendorf, C.; Ahlin, G.; Seithel, A.; Artursson, P.; Ungell, A.; Karlsson, J. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab. Dispos. 2007, 35, 1333–1340.
8. Abolhoda, A.; Wilson, A.; Ross, H.; Danenberg, P.V.; Burt, M.; Scotto, K.W. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin. Cancer Res. 1999, 5, 3352–3356.

9. Haber, M.; Smith, J.; Bordow, S.; Flemming, C.; Cohn, S.; London, W.; Marshall, G.; Norris, M. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of neuroblastoma. J. Clin. Oncol. 2006, 24, 1546–1553.
10. Genevieve Housman, Shannon Byler, Sarah Heerboth , Karolina Lapinska , Mckenna Longacre , Nicole Snyder and Sibaji Sarkar. Drug Resistance in Cancer: An Overview, ISSN 2072-6694 Cancers 2014, 6, 1769-1792
11. A. Szilagyi, J. Kardos, S. Osvath, L. Barna, P. Zavodszky, Protein Folding: The Protein Folding Problem, Springer-Verlag Berlin Heidelberg, 2007, 4-6
12. Ramaen, O., Leulliot, N., Sizun, C., Ulryck, N., Pamlard, O., Lallemand, J.-Y., Van Tilbeurgh, H., Jacquet, E, Structure of the Human Multidrug Resistance Protein 1 Nucleotide Binding Domain 1 Bound to Mg(2+)/ATP Reveals a Non-Productive Catalytic Site, 2006 J.Mol.Biol. 359: 940
13. K. M. Kumar, Anand Anbarasu and Sudha Ramaiah; Molecular docking and molecular dynamics studies on b-lactamases and penicillin binding proteins; Mol. BioSyst., 2014, 10, 891—900.
14. Vivek Chandramohan, Anubhav Kaphle,Mamatha Chekuri, Sindhu Gangarudraiah, and Gowrishankar Bychapur Siddaiah; Evaluating Andrographolide as a Potent Inhibitor of NS3-4A Protease and Its Drug-Resistant Mutants Using In Silico Approaches; Hindawi Publishing Corporation; Advances in Virology; Volume 2015, Article ID 972067, 9.
15. G. Wu, D. H. Robertson, C. L. Brooks, and M. Vieth, “Detailed analysis of grid-basedmolecular docking: a case study of CDOCKER—a CHARMm-based MD docking algorithm,” Journal of Computational Chemistry, 2003.vol. 24, no. 13, pp. 1549–1562.
16. David Eisenberg; The discovery of the α-helix and β-sheet, the principal structural features of proteins; 2003; vol. 100 no. 20, 11207-11210